PRESS RELEASE published on 05/03/2023 at 22:05, 3 years 6 months ago Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA) to be Presented at the 2023 ASGCT Annual Meeting
PRESS RELEASE published on 05/02/2023 at 23:15, 3 years 6 months ago Moderna Announces Establishment of an Enterprise Solutions Hub and Commercial Operations in The Philippines
PRESS RELEASE published on 04/20/2023 at 22:05, 3 years 6 months ago Moderna to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023
PRESS RELEASE published on 04/20/2023 at 13:30, 3 years 6 months ago Moderna and IBM to Explore Quantum Computing and Generative AI for mRNA Science
PRESS RELEASE published on 04/16/2023 at 17:00, 3 years 6 months ago Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following C
PRESS RELEASE published on 04/11/2023 at 13:00, 3 years 7 months ago Moderna Announces Clinical and Program Updates at 4th Vaccines Day
PRESS RELEASE published on 04/06/2023 at 23:00, 3 years 7 months ago MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melan
PRESS RELEASE published on 03/30/2023 at 13:00, 3 years 7 months ago Moderna Finalizes Agreement with the Government of the Republic of Kenya to Establish an mRNA Manufacturing Facility
PRESS RELEASE published on 03/24/2023 at 12:30, 3 years 7 months ago Moderna to Host Fourth Annual Virtual Vaccines Day on April 11, 2023
PRESS RELEASE published on 03/23/2023 at 12:02, 3 years 7 months ago Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines
Published on 11/14/2026 at 12:56, 22 hours 39 minutes ago Gabriel Announces Dismissal of ICSID Annulment Application
Published on 11/14/2026 at 01:30, 1 day 10 hours ago NuRAN Wireless Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Published on 11/14/2026 at 00:40, 1 day 10 hours ago BEACN Announces Annual General and Special Meeting Results
Published on 11/14/2026 at 00:35, 1 day 11 hours ago American Hotel Income Properties REIT LP Reports Q3 2026 Results
Published on 11/14/2026 at 00:00, 1 day 11 hours ago SLAM Announces Proposed Extension of Warrant Expiry Dates
Published on 11/13/2026 at 23:24, 1 day 12 hours ago EQS-Adhoc: ASOS PLC: Repurchase of £90m of 2028 Convertible Bonds
Published on 11/13/2026 at 21:52, 1 day 13 hours ago EQS-Adhoc: Airbus reports share buyback transactions 9-13 November 2026
Published on 11/13/2026 at 19:08, 1 day 16 hours ago EQS-Adhoc: CHAPTERS Group AG: Successful Completion of Private Placement of the Capital Increase from Authorized Capital Resolved on November 13, 2026
Published on 11/13/2026 at 19:00, 1 day 16 hours ago Assemblée générale ordinaire des actionnaires le 18 décembre 2026
Published on 11/13/2026 at 11:35, 2 days ago ENGIE and Google to partner on energy solutions for a potential data center project near Châteauroux, France
Published on 11/13/2026 at 11:35, 2 days ago ENGIE et Google s’associent pour développer les solutions énergétiques d’un projet de data center envisagé près de Châteauroux, en France
Published on 11/13/2026 at 08:00, 2 days 3 hours ago Résultats trimestriels au 30 septembre 2026 - ANR par action : 101,54 €, en progression de + 7,8 % sur 9 mois - Capitaux propres consolidés : 772 M€
Published on 11/12/2026 at 23:12, 2 days 12 hours ago Belgrano continues the implementation of its public share buyback offer (OPRA)
